Doses that appeared in studies, not a plan for you.

Evidence at a glance

Safety overview · Questions for your doctor

A closer reading

Why "doses used in studies" is the only honest answer

When people search for a citicoline (CDP-choline) dose, they usually want a single number. This page does not give one, and that is a deliberate choice, not a gap. The only numbers this site can stand behind are the ones that appeared in published clinical trials, roughly 250 to 2,000 mg per day. That span describes what researchers chose to test in groups of volunteers under controlled conditions. It does not describe what any individual reader should take.

There is a real difference between those two things. A trial dose is selected for a study population with a defined condition, under monitoring, often alongside other treatments. Your situation includes your age, your health, your diet, your other supplements, and any prescription drugs you take. None of that was in the trial. Copying a number from a paper and applying it to yourself skips the part of medicine that actually matters, which is fitting an intervention to a person.

So treat the figures on this page as context for reading research, not as a menu. If you and your doctor decide citicoline is worth trying, the dose conversation belongs in that room.

What the trial range actually tells you

The range of about 250 to 2,000 mg per day is wide, and the width itself is information. It tells you that researchers have not settled on one standard dose, even within a single condition. Different trials asked different questions, used different formulations, and ran for different lengths of time.

It also tells you something about safety data. Across those trials, citicoline was generally well tolerated, with the most common complaints being mild stomach upset, headache, and insomnia. That tolerability picture comes from the same studies that produced the dose range, so the two belong together. A dose you have seen in a trial is a dose for which at least some human safety data exists. A dose above that range is outside the studied evidence, and claims about it rest on nothing this site can verify.

What the range does not tell you is where benefit, if any, begins. Trials were not designed to find a minimum effective dose for a healthy buyer. Most compared one fixed dose against placebo and reported the group result. That is a different question from "how much should I take," and it is the question almost nobody asks in marketing copy.

The attention trial numbers, in context

The two figures this site names specifically, 250 mg and 500 mg per day, come from the McGlade 2012 attention trial in healthy adult women. Participants taking those doses scored better on attention tests than participants taking placebo. A related small trial in adolescent males reported gains in attention and psychomotor speed at studied doses.

Three cautions apply before you treat those numbers as a recommendation.

First, both trials were small. Small trials can produce results that do not hold up when the experiment is repeated at scale. The citicoline literature itself contains a famous example of this, described in the next section.

Second, both trials were funded by the maker of Cognizin, a branded form of citicoline. Industry funding does not prove a result is wrong, but it is a reason to want independent confirmation, which does not yet exist for these findings. Cognizin is also not a different molecule. It is a brand of the same compound, so these results say nothing unique about one product over another.

Third, "better scores on an attention test" is a narrow outcome. It is not the same as sharper thinking at work, better grades, or any benefit you would notice in daily life. Even if you accept the result at face value, the trial does not tell you that 250 mg will do anything you can feel.

Bigger doses did not rescue bigger trials

The most important dosing lesson in the citicoline literature comes from the largest and best-run studies, and it cuts against optimism.

The ICTUS trial, published in The Lancet in 2012, enrolled about 2,300 people with acute stroke. It remains the largest citicoline trial ever conducted, and it found no improvement in 90-day recovery compared with placebo. Earlier meta-analyses of smaller stroke trials had suggested benefit. The largest test did not confirm it. Whatever dose those smaller studies used, scaling up the evidence erased the apparent effect.

The COBRIT trial, published in JAMA in 2012, asked whether citicoline improved outcomes after traumatic brain injury. It did not. Functional and cognitive results were no better than placebo.

These were not underpowered pilot studies. They were the trials most likely to find a real effect if one existed, and they found none. This matters for dosing because it undercuts the intuitive idea that there must be some amount of citicoline that works for serious brain conditions. That idea was tested directly, at scale, and failed.

Sudden facial droop, arm weakness, or speech difficulty can be a stroke. Call 911 immediately. No supplement, at any dose, is a response to those symptoms.

"More is better" is not in the evidence

Supplement labels often compete on milligrams. The register of evidence does not support reading a higher number as a better product.

No citicoline trial establishes a dose-response curve that a consumer can use. The studies compared fixed doses against placebo, not dose against dose in a way that maps onto buying decisions. A 1,000 mg capsule is not twice as proven as a 500 mg capsule. In several conditions, the honest summary is that no dose proved effective at all in the strongest trials.

There is also a mismatch problem. If the study relevant to your question used 250 mg and 500 mg, a label advertising 1,000 mg is not offering you "more of the studied effect." It is offering you a dose that was not tested for that question. The reverse is also true. A product matching a trial's milligram count still is not the trial, because you are not the trial population.

The practical move is to line the label up against the evidence before assuming the numbers mean anything. How to read a label walks through that process. What Cognizin is explains the brand question, and CDP-choline and citicoline explains why the two names refer to one compound.

Splitting doses, timing, and other schedule questions

Readers often ask whether a daily amount should be taken all at once or divided, with food or without, morning or night. This page cannot answer those questions, because the trials were not designed to answer them for you.

Study protocols specify schedules so that every participant is treated the same way. That standardization is a research tool. It is not evidence that the chosen schedule is optimal, and it is definitely not a schedule prescribed for you. Quoting a paper's dosing schedule as if it were instructions would be exactly the kind of overreach this site exists to avoid.

Insomnia is one of the mild side effects reported in trials, which is a reasonable detail to raise with your doctor if timing concerns you. Beyond that, schedule questions are clinical questions. Citicoline side effects covers tolerability in more depth.

Who needs a doctor in the loop before any dose

Everyone does, but some readers more urgently than others.

People with Parkinson's disease sit at the top of the list. Evidence suggests citicoline may enhance the effects of levodopa. That interaction cuts both ways: it could be useful or it could push dopaminergic effects too far. This is a decision for the neurologist managing the medication, not for a label.

Pregnant and breastfeeding readers should know that safety data in those groups are lacking. Absence of evidence is not evidence of safety.

Anyone combining citicoline with prescription drugs, managing a recent stroke or brain injury, or considering it for a memory problem should bring the actual product and the actual dose to an actual appointment. Questions to ask your doctor is built for that conversation. The safety overview collects the broader picture.

How to use this page going forward

Use the 250 to 2,000 mg range as a reality check. A claim attached to a dose outside that span has no trial evidence behind it. A claim attached to a dose inside that span still needs to match the right condition, the right population, and a trial that actually found something, because the largest stroke and brain injury trials found nothing at any dose they used.

Then stop at that point. The next step is not a bigger number or a cleverer schedule. It is a conversation with someone who knows your health history. That is the only dosing protocol this site will ever endorse.